Stockscreener 앱 받기
26.07
0.27%
0.07
전일 마감가:
$26.00
열려 있는:
$25.94
하루 거래량:
284.55K
Relative Volume:
0.72
시가총액:
$1.20B
수익:
$722.68M
순이익/손실:
$134.71M
주가수익비율:
9.764
EPS:
2.67
순현금흐름:
$109.94M
1주 성능:
-6.02%
1개월 성능:
+1.80%
6개월 성능:
+22.57%
1년 성능:
-26.89%
1일 변동 폭
$25.42
$26.23
1주일 범위
$25.42
$29.52
52주 변동 폭
$20.39
$37.66
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
명칭
Amphastar Pharmaceuticals Inc
전화
909-980-9484
주소
11570 SIXTH STREET, RANCHO CUCAMONGA, CA
AMPH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMPH
Amphastar Pharmaceuticals Inc
|
26.07 | 1.19B | 722.68M | 134.71M | 109.94M | 2.67 |
|
ZTS
Zoetis Inc
|
124.65 | 55.21B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.16 | 51.59B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.83 | 43.51B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.76 | 37.11B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
464.93 | 20.32B | 3.08B | 1.24B | 1.07B | 25.61 |
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Equal Weight |
| 2025-08-12 | 업그레이드 | Needham | Hold → Buy |
| 2025-05-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-02-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-11-22 | 개시 | Wells Fargo | Equal Weight |
| 2024-03-05 | 개시 | JP Morgan | Overweight |
| 2023-11-17 | 개시 | BofA Securities | Neutral |
| 2023-07-25 | 재개 | Jefferies | Buy |
| 2022-10-21 | 재개 | Jefferies | Buy |
| 2022-07-29 | 개시 | CapitalOne | Overweight |
| 2022-01-07 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-01-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-10-05 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2020-05-01 | 개시 | Northland Capital | Outperform |
| 2019-03-13 | 다운그레이드 | Needham | Buy → Hold |
| 2019-03-13 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2018-08-10 | 재확인 | Needham | Buy |
| 2018-03-13 | 재확인 | Needham | Buy |
| 2017-12-01 | 재확인 | Needham | Buy |
| 2017-11-09 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2017-09-27 | 재확인 | Needham | Buy |
| 2017-03-14 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2016-08-09 | 재확인 | Needham | Buy |
| 2016-05-10 | 재확인 | Needham | Buy |
| 2016-02-19 | 개시 | Wells Fargo | Outperform |
| 2015-06-19 | 재확인 | Needham | Buy |
| 2015-06-03 | 개시 | Raymond James | Strong Buy |
| 2014-07-21 | 개시 | Needham | Buy |
모두보기
Amphastar Pharmaceuticals Inc 주식(AMPH)의 최신 뉴스
Is the Options Market Predicting a Spike in Amphastar (AMPH) Stock? - sharewise.com
Why Amphastar Pharmaceuticals (AMPH) Stock Is Nosediving - Finviz
A Look At Amphastar Pharmaceuticals (AMPH) Valuation After The AMP-110 License Agreement With Nanjing Hanxin - Yahoo Finance
Amphastar Pharmaceuticals Touts Shift to Proprietary Drugs, Teases AMP-007 Launch and Baqsimi Growth - MarketBeat
2 Reasons to Avoid AMPH and 1 Stock to Buy Instead - Finviz
Aug Opening: Will Amphastar Pharmaceuticals Inc stock recover faster than peers2025 Price Targets & Smart Investment Allocation Tips - Bộ Nội Vụ
Earnings Recap: Will Amphastar Pharmaceuticals Inc stock pay special dividends2025 Big Picture & Capital Protection Trade Alerts - Bộ Nội Vụ
Amphastar licenses synthetic ACTH analog for inflammatory conditions By Investing.com - Investing.com Nigeria
Amphastar Pharmaceuticals, Inc. (AMPH): Investor Outlook With A 7.39% Upside Potential - DirectorsTalk Interviews
Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Up Today - Finviz
Amphastar Licenses ACTH Analog AMP-110 for North America - TipRanks
Amphastar Pharmaceuticals Signs Multiple Material Agreements - TradingView — Track All Markets
Amphastar, Hanxin Enter Exclusive License Agreement for AMP-110 - Contract Pharma
Amphastar licenses synthetic ACTH analog for inflammatory conditions - Investing.com
Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound - ACCESS Newswire
New synthetic hormone treatment targets autoimmune and inflammatory conditions - Stock Titan
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Could Be Riskier Than It Looks - 富途牛牛
The Bull Case For Amphastar Pharmaceuticals (AMPH) Could Change Following New BofA Coverage And JPM Spotlight - Yahoo Finance
Is Amphastar Pharmaceuticals Inc. stock a smart buy before Fed meetingExit Point & Daily Profit Focused Screening - Улправда
(AMPH) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Is Amphastar Pharmaceuticals (AMPH) Attractively Priced After Recent Share Price Weakness? - Sahm
Amphastar Pharmaceuticals, Inc. $AMPH Stock Holdings Trimmed by CX Institutional - MarketBeat
Why Amphastar Pharmaceuticals Inc. stock remains undervaluedJuly 2025 PostEarnings & Expert-Curated Trade Recommendations - Улправда
Assessing Amphastar Pharmaceuticals (AMPH) Valuation After Recent Share Price Momentum - Sahm
Will Amphastar Pharmaceuticals Inc. stock benefit from AI adoption2025 Support & Resistance & Fast Entry High Yield Stock Tips - Улправда
Is Amphastar Pharmaceuticals Inc. stock affected by interest rate hikesWeekly Profit Report & High Return Trade Opportunity Guides - ulpravda.ru
Amphastar Pharmaceuticals to Present at the J.P. Morgan 2026 Healthcare Conference - ACCESS Newswire
Amphastar Expands BAQSIMI® Distribution in Asia - MSN
Value Recap: Is Amphastar Pharmaceuticals Inc stock trading near support levels2025 Technical Patterns & Weekly Breakout Watchlists - moha.gov.vn
Amphastar Pharmaceuticals, Inc. $AMPH Shares Sold by Pacer Advisors Inc. - MarketBeat
What analysts say about Amphastar Pharmaceuticals Inc stockTake Profit Strategies & Outstanding Investment Portfolio - earlytimes.in
Amphastar Director Sells 16,679 Shares for $441,800 - AOL.com
Amphastar Pharmaceuticals Inc Stock Analysis and ForecastVolatility Index Analysis & Swing Trade Smarter With Data Insights - earlytimes.in
Will Amphastar Pharmaceuticals Inc. stock split again soonStock Screening Results & Make Confident Moves With Forecasting Models - bollywoodhelpline.com
Is Amphastar Pharmaceuticals Inc stock affected by interest rate hikesShort Setup & Reliable Intraday Trade Alerts - moha.gov.vn
How supply chain issues affect Amphastar Pharmaceuticals Inc. stockInstitutional Holding Changes & Minimal Investment Portfolio - bollywoodhelpline.com
Responsive Playbooks and the AMPH Inflection - Stock Traders Daily
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
129,339 Shares in Amphastar Pharmaceuticals, Inc. $AMPH Purchased by Rice Hall James & Associates LLC - MarketBeat
Squarepoint Ops LLC Lowers Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar Pharmaceuticals’ Resilient Q3 2025 Earnings Call - MSN
Amphastar Pharmaceuticals, Inc. (AMPH) Stock Analysis: Exploring a Potential 16.08% Upside for Investors - DirectorsTalk Interviews
A Fresh Look at Amphastar Pharmaceuticals (AMPH) Valuation After Recent Share Price Stabilisation - Sahm
Will Amphastar Pharmaceuticals Inc. stock outperform international peersJuly 2025 Review & Community Trade Idea Sharing Platform - Улправда
Can Amphastar’s Recent Rebound Signal a Compelling Opportunity in 2025? - Sahm
Is Amphastar Pharmaceuticals Inc. (29A) stock dividend growth reliable2025 AllTime Highs & High Conviction Buy Zone Alerts - Улправда
Why Amphastar Pharmaceuticals Inc. (29A) stock could be top winnerJuly 2025 Price Swings & Weekly Stock Breakout Alerts - Улправда
Why retail investors favor Amphastar Pharmaceuticals Inc. stockTreasury Yields & Daily Entry Point Trade Alerts - Улправда
Amphastar Pharmaceuticals Inc (AMPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Amphastar Pharmaceuticals Inc 주식 (AMPH) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Zhou Rong | SENIOR EVP, PRODUCTION CENTER |
Dec 17 '25 |
Sale |
26.20 |
9,787 |
256,379 |
138,043 |
| Petersen Floyd F. | Director |
Dec 12 '25 |
Sale |
25.92 |
2,426 |
62,888 |
71,368 |
| Petersen Floyd F. | Director |
Dec 11 '25 |
Sale |
25.69 |
1,737 |
44,620 |
73,794 |
1.30%
1.45%
자본화:
|
볼륨(24시간):